Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines

Gene Therapy

Volumn 3, Issue 9, 1996, Pages 819-824

  Schweighoffer, T ^a   Schmidt, W ^a   Buschle, M ^a   Birnstiel, M L ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Cancer vaccine; Interleukin 2; T cells

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2; L SELECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; LYMPH NODE; MELANOMA; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; L-SELECTIN; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED DBA; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINATION;

ANIMALIA;

EID: 0029794846     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995; 13: 399-415.
2. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
3. Pardoll D. Cancer vacccines. Immunol Today 1993; 14: 310-316.
4. Shimizu Y et al. Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1 and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 1991; 113: 1203-1212.
5. Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today 1992; 13: 106-112.
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
7. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med 1990; 171: 801-817.
8. Mackay CR, Marston W, Dudler L. Altered patterns of T cell migration through lymph nodes and skin following antigen challenge. Eur J Immunol 1992; 22: 2205-2210.
9. Anderson AO. Structure and Organization of the Lymphatic System. Oxford University Press: New York, 1990, pp 14-45.
10. Reichert RA, Gallatin WM, Butcher EC, Weissman IL. A homing receptor-bearing cortical thymocyte subset: implications for thymus cell migration and the nature of cortisone-resistant thymocytes. Cell 1984; 38: 89-99.
11. Lasky LA et al. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell 1992; 69: 927-938.
12. Imai Y, Lasky LA, Rosen SD. Sulphation requirement for Gly-CAM-1, an endothelial ligand for L-selectin. Nature 1993; 361: 555-557.
13. Mackay CR. Homing of naive, memory and effector lymphocytes. Curr Opin Immunol 1993; 5: 423-427.
14. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983; 304: 30-34.
15. Arbones ML et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1994; 1: 247-260.
16. Picker LJ et al. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition. J Immunol 1993; 150: 11050-11121.
17. Hou S et al. Subverting lymph node trafficking by treatment with the Mel-14 monoclonal antibody to L-selectin does not prevent an effective host response to Sendai virus. J Immunol 1995; 155: 252-258.
18. Wagner E et al. Coupling of adenovirus to transferrinpolylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992; 89: 6099-6103.
19. Zatloukal K et al. Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'. Gene 1993; 135: 199-207.
20. Zatloukal K et al. Elicitation of a systemic and protective antimelanoma immune response by an IL-2 based vaccine: assessment of critical cellular and molecular parameters. J Immunol 1995; 154: 3406-3419.
21. - T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149: 3627-3635.
22. Maass G et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1994; 92: 5540-5544.
23. Lepault F, Gagnerault MC, Faveeuw C, Boitard C. Recirculation, phenotype and functions of lymphocytes in mice treated with monoclonal antibody MEL-14. Eur J Immunol 1994; 24: 3106-3112.
24. Bradley LM, Watson SR, Swain SL. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med 1994; 180: 2401-2406.
25. Waldmann TA. The multi-subunit interleukin-2 receptor. Ann Rev Biochem 1989; 58: 875-911.
26. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immmunol Today 1994; 15: 479-483.
27. Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989; 245: 1238-1241.
28. Watson SR, Fennie C, Lasky LA. Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimaera. Nature 1991; 349: 164-167.
29. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med 1995; 181: 2259-2264.
30. Bosse R, Vestweber D. Only simultaneous blocking of the L- and P-selectin completely inhibits neutrophil migration into mouse peritoneum. Eur J Immunol 1994; 24: 3019-3024.
31. Larsen CP et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483-1493.
32. Gansbacher B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
33. Karp SE et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 1993; 150: 896-905.
34. Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716.
35. Hock H et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774-2778.
36. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994; 152: 2324-2332.
37. Huang AYC et al. Role of bone marrow-derived cells in presenting MHC class-I restricted tumor antigens. Science 1994; 264: 961-965.
38. - T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
39. Liu Y et al. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med 1992; 175: 437-445.
40. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154: 2794-2800.
41. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
42. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment and effector function of antitumor T cells. J Exp Med 1994; 179: 1205-1214.
43. Wu TC et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182: 1415-1421.
44. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.